Advances in the study of vincristine an anticancer ingredient from Gatharanthus roseus

Zhongguo Zhongyao Zazhi

Volumn 28, Issue 11, 2003, Pages 1008-1009

  Lu, Yi ^a   Hou, Shi Xiang ^a   Chen, Tong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Clinic; New drug delivery system; Properties; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; LIPOSOME; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL; BREAST TUMOR; CATHARANTHUS; CHEMISTRY; HUMAN; ISOLATION AND PURIFICATION; LIVER TUMOR; MEDICINAL PLANT; REVIEW; STOMACH TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CATHARANTHUS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIPOSOMES; LIVER NEOPLASMS; PLANTS, MEDICINAL; STOMACH NEOPLASMS; VINCRISTINE;

EID: 24644512324     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Journey L J, Burdman J. Ultrastructural Studies on Tissue Culture Cells Treated with Vincristine. Cancer Chemother Rep, 1968, 52(4):509.
2. Lobert S, Vulevic B, Correin J J. Interaction of Vinca Alkaloids with Tubulin: a Comparison of Vinblastine, Vincristine, and Vinorelbine. Biochemistry, 1996,35(21):6806.
3. Nelson R L, Dyke R W, Root M A. Comparative Pharmacokinetics of Vindesine, Vincristine and Vinblastine in Patients' with Cancer. Cancer Treat Rev, 1980, 7(1):17.
4. Jackson D V Jr, Sethi V S, Spurr C L, et al. Pharmacokinetics of Vincristine Infusion. Cancer Treat Rep, 1981, 65(11-12):1043.
5. Kaba K, Tani E, Morimura T, et al. Potentiation of Vincristine Effect in Human and Murine Gliomas by Calcium Channel Blockers Calmodulin Inhibitors. J Neurosurg, 1985,63(6):905.
6. Rowland G F, Simmonds R G, Gore V A. Drug Localisation and Growth Inhibition Studies of Vindesine-monoclonal Anti-CEA Conjugates in a Human Tumour Xenograft. Cancer-Immunol-Immunother, 1986,21(3):183.
7. Hurwitz E, Levy R, Maron R. The Covalent Binding of Daunomycin and Adria Mycin to Antibodies, with Retention of Both Drug and Antibody Activities. Cancer Res, 1975, 35(5):1175.
8. Webb M S, Harasym T O, Masin D, et al. Sphingomyelin-cholesterol Liposomes Significantly Enhance the Pharmacokinetic and Therapeutic Properties of Vincristine in Murine and Human Tumour Models. Br J Cancer, 1995 10;72(4):896.
9. Webb M S, Logan P, Kanter P M, et al. Preclinical Pharmacology, Toxicology and Efficacy of Sphingomyelin/cholesterol Liposomal Vincristine for Therapeutic Treatment of Cancer. Cancer Chemother Pnarmacol,1998,42(6):461.
10. Krishna R, Webb M S, St Onge G, et al. Liposomal and Nonliposomal Drug Pharmacokinetics after Administration of Liposome-encapsulated Vincristine and Their Contribution to Drug Tissue Distribution Properties. J Pharmacol Exp Ther,2001 9;298(3): 1206.
11. Boman N L, Tron V A, Bally M B, et al. Vincristine-induced Dermal Toxicity is Significantly Reduced when the Drug is Given in Liposomes. Cancer Chemother Pharmacol,1996,37(4):351.